Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of JNJ-55375515 in healthy male volunteers
NL-OMON46723Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in affective disorder and major depressive disorder (MDD) comparing JNJ-55375515 sequence with Placebo sequence (2 arms). Primary endpoint: Safety and tolerability of daytime and nighttime dosing. Started Jan 2018; status: completed.
02
Drugs
JNJ-55375515
03
Conditions
affective disordermajor depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON46723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46723.